Plain-English translation of NCT06056115 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment approach for people with advanced lung adenocarcinoma (a type of lung cancer) that has spread to the brain. The study combines a medication called tislelizumab—which works by helping your immune system fight cancer—with standard platinum-based chemotherapy. Researchers want to see if this combination is effective and safe for patients whose brain metastases (cancer spread) are not yet causing symptoms.
Brain metastasis is a serious complication of lung cancer and limits treatment options for many patients. This medication has shown promise in cancer treatment, and this trial aims to find out whether combining it with chemotherapy can improve outcomes for patients whose cancer has spread to the brain.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive tislelizumab (the immune-boosting medication) combined with platinum-based chemotherapy as your first-line treatment for your lung cancer. The trial will monitor how well the treatment works and track any side effects through imaging scans and other tests. You would also likely have blood work and possibly tissue samples collected to help researchers understand how the medication is working and why some patients may respond better than others.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China